WCLC 2022 – Maximilian Hochmair
Maximilian Hochmair highlights relevant study data in the field of EGFR-mutated advanced lung cancer, novel therapies in the management of KRAS p.G12C mutation as well as MET exon 14 skipping mutations in NSCLC. He draws attention to antibody drug conjugates in the management of NSCLC patients as well as the optimal treatment sequence in the ALK-positive setting.
Here is the full WCLC 2022 report.
More posts
Immune-based strategies are raising hope in small-cell tumors
Immune-based strategies are raising hope in small-cell tumors DeLLphi-300: tarl
Stage I-III disease: surgical and systemic options
Stage I-III disease: surgical and systemic options SLR as new standard of care
Promising findings across oncogenic targets
Promising findings across oncogenic targets Amivantamab plus lazertinib in EGFR
Preface – WCLC 2022
Preface – WCLC 2022 © Private – Michael Thomas, MD, PhD, Head of the Depar
